Molecular Communication-Based Intelligent Dopamine Rate Modulator for Parkinson’s Disease Treatment

Parkinson’s disease (PD) is a progressive neurodegenerative disease, and it is caused by the loss of dopaminergic neurons in the basal ganglia (BG). Currently, there is no definite cure for PD, and available treatments mainly aim to alleviate its symptoms. Due to impaired neurotransmitter-based information transmission in PD, molecular communication-based approaches can be employed as potential solutions to address this issue. Molecular Communications (MC) is a bio-inspired communication method utilizing molecules to carry information. This mode of communication stands out for developing bio-compatible nanomachines for diagnosing and treating, particularly in addressing neurodegenerative diseases like PD, due to its compatibility with biological systems. This study presents a novel treatment method that introduces an Intelligent Dopamine Rate Modulator (IDRM), which is located in the synaptic gap between the substantia nigra pars compacta (SNc) and striatum to compensate for insufficiency dopamine release in BG caused by PD. For storing dopamine in the IDRM, dopamine compound (DAC) is swallowed and crossed through the digestive system, blood circulatory system, blood-brain barrier (BBB), and brain extracellular matrix uptakes with IDRMs. Here, the DAC concentration is calculated in these regions, revealing that the required exogenous dopamine consistently reaches IDRM. Therefore, the perpetual dopamine insufficiency in BG associated with PD can be compensated. This method reduces drug side effects because dopamine is not released in other brain regions. Unlike other treatments, this approach targets the root cause of PD rather than just reducing symptoms.